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The sixth annual Vaccine Renaissance Conference, hosted 
by the Institute for Immunology and Informatics (iCubed) 
at the University of Rhode Island, was held in Providence, RI 
on October 15–17, 2012. This conference provides a forum for 
the review of current progress in vaccine discovery and devel-
opment, and creates an environment for the exchange of ideas. 
In this issue of Human Vaccines & Immunotherapeutics (HV&I), 
seven Vaccine Renaissance Conference speakers will showcase 
their work; below, we describe a few of the conference high-
lights. The first session, “Developments in Homeland Security: 
From Microbe Hunters to Vaccines on Demand,” started the 
conference with a warning from an expert in the field about the 
importance of preparing for well-defined biowarfare threats. Joel 
McCleary, the chairman and co-founder of Q Global, founder of 
PharmAthene, Inc., and former aide to President Jimmy Carter, 
presented a historical overview of the US bioweapons program 
and summarized his take on current bio-threats,1 which include 
tularemia and Staphylococcal enterotoxin B.2 McCleary stated that 
the US should plan to have enough of these vaccines stockpiled 
for the entire country and reminded the audience that there is no 
tularemia vaccine at present. He also emphasized that a bioter-
ror attack would overwhelm victims’ immune systems due to the 
high dose of pathogen, and consequently, traditional small mol-
ecule drugs like antibiotics would be ineffective for those near the 
epicenter of an attack.
Following on the topic of biodefense, Dr Daniel Wolfe and 
colleagues from the Joint Science and Technology Office of the 
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Defense Threat Reduction Agency (DTRA) addressed the need 
for a tularemia vaccine highlighted by McCleary. In the current 
issue of HV&I, Wolfe et al. identified a lead candidate (Lm-IgIC) 
that protects F344 rats against an aerosol challenge of F. tularen-
sis and established a non-human primate model for aerosolized F. 
tularensis Type A.3 DTRA has also submitted an Investigational 
New Drug (IND) application for a Phase I clinical trial to test 
a Venezuelan Equine Encephalitis Virus (VEEV) DNA vaccine. 
A ricin vaccine, RVEc, is under development as well; acceptable 
safety and immunogenicity have been demonstrated in non-
human primates, and Phase I clinical trials for RVEc began in 
May 2011.
Despite important advances in the strategic preparedness of 
the US agencies for biowarfare preparedness, delays in vaccine 
design, development, and manufacture remain significant obsta-
cles to effective national biodefense. This is particularly true for 
the very real threat of novel pathogens and emerging influenza 
pandemic strains. Conventional approaches to vaccine develop-
ment and production are incompatible with the prompt deploy-
ment needed for an effective public health response. One potential 
solution to the problem is developing vaccines on demand, as 
elucidated by Dr Mark Poznansky, Director of the Vaccine and 
Immunotherapy Center at the Massachusetts General Hospital. 
Poznansky provided an overview of the DARPA-funded program 
for rapid vaccine production that was established in 2011 and 
executed in 2012; the VaxCelerate Consortium features local bio-
tech company EpiVax, Inc. as one of its members.
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viral infection. These findings have important implications for 
future development of vaccines and therapeutics. Correlates of 
protection were also explored by Dr Sharone Green (University 
of Massachusetts Medical School), who described how the 
mechanisms behind heterologous secondary infections could be 
exploited for rational vaccine design.8 Green et al. demonstrated 
protection against secondary heterologous Japanese encephalitis 
virus infection in a murine model following primary infection 
with West Nile virus. These results have broad implications for 
neglected tropical disease vaccine development, as cross-con-
served epitopes could be selected to create broadly protective 
flavivirus vaccines.
The health of animals has a significant bearing on the health 
of humans (infectious diseases in particular), and this served as 
the impetus behind the “Animal Vaccines and Human Health” 
session. Dr Jennifer Steele and her colleagues at Tufts University 
Cummings School of Veterinary Medicine reported how hyperim-
mune bovine colostrum (HBC) harvested from cows vaccinated 
during gestation can be used to treat gastrointestinal infections 
in humans. HBC, which is rich in targeted immunoglobulins, 
has demonstrated efficacy in treating or preventing numerous 
diseases, including Clostridium difficile infection (CDI). Steele et 
al. inoculated cows with a novel recombinant vaccine containing 
the two most important virulence factors of C. difficile, TcdA and 
TcdB, and demonstrated in preliminary results that this HBC 
product successfully treated CDI in the gnotobiotic piglet model. 
Steele notes in the current issue of HV&I that HBC could be 
utilized as a valuable alternative to traditional antibiotic treat-
ment, which would have the added benefit of lowering the risks of 
damage to the gut microflora, disease recurrence, and antibiotic 
resistance.9
Animal vaccination can additionally be applied to the prob-
lem of Lyme disease, as demonstrated by Dr Samuel Telford 
(Tufts University Cummings School of Veterinary Medicine). 
Telford argued that “vector control” such as mass vaccination 
of local mouse populations could be implemented concurrently 
with a revival of the Lymerix vaccine to halt the spread of Lyme 
disease.10 Although the Lymerix vaccine demonstrated 50–70% 
efficacy in a Phase II clinical trial, Smith Kline Beecham with-
drew the product due to pressure from advocacy groups and poor 
sales. In a review of Lyme disease pathology and the history of 
Lymerix, Telford found no peer-reviewed evidence of arthritis as 
a side effect, even 10 years post vaccination. Telford believes that 
Lymerix is both safe and effective in preventing Lyme disease, 
which would be of great interest to those who reside in, or visit, 
rural areas.
Dr Peter Burkhard, Associate Professor at the University of 
Connecticut and CEO of Alpha-O Peptides AG, rounded out 
this session with a presentation of his work to develop a protein 
nanoparticle vaccine against rodent malaria. The P4c-Mal vac-
cine tested by Burkhard et al. conferred long-lasting immunity 
against Plasmodium berghei sporozoite challenge in BALB/c and 
C57Bl/6 mice,12 while a prototype P. falciparum human-indi-
cated vaccine demonstrated protection against lethal challenge in 
Wild Type and MHC I knockout C57Bl/6 mice.13 As Burkhard 
noted, this vaccine platform has a wide range of applications 
Dr Anne De Groot continued this discussion by detailing 
progress on “FastVax,” a program to produce vaccines on demand 
for biodefense. De Groot outlined the feasibility of producing a 
vaccine for a novel biowarfare agent within 60 days, which would 
be 2-fold faster than the rate at which the most recent pandemic 
influenza vaccine was produced. The rapid, nimble vaccine design 
tools and production technologies currently in use at iCubed and 
EpiVax can significantly accelerate vaccine development while 
enhancing national security against emerging pathogens and bio-
warfare agents. In her article in an upcoming issue of HV&I, De 
Groot will report on an innovative and distributed solution to 
the need for rapid vaccine production capability, and suggests 
this approach might be highly relevant to the development of a 
vaccine for emerging H7N9 influenza.4
The focus of the conference then shifted from vaccines for 
bioterror applications to vaccines for emerging and re-emerging 
tropical diseases in the session entitled, “Neglected Tropical 
Diseases.” Dr Stephen Thomas, director of the Viral Diseases 
Branch at the Walter Reed Army Institute of Research, described 
the high social, financial, and healthcare resource costs caused by 
the millions of dengue virus infections each year. He stressed that 
a safe, efficacious, and widely used dengue vaccine in conjunc-
tion with strategic vector control is necessary to reduce the global 
dengue burden. As no correlates of protection or validated animal 
model of dengue disease have yet been defined, Thomas advo-
cated for continued exploration of the dengue human infection 
model with partially attenuated dengue viruses to advance den-
gue vaccine development. In the current issue of HV&I,5 Thomas 
describes the potential application of this human infection model 
to the development of new vaccines and therapeutics.
Also in the neglected tropical diseases session, Dr Jonathan 
Kurtis (Warren Alpert Medical School of Brown University) 
detailed his exciting progress toward a vaccine candidate for 
pediatric Plasmodium falciparum malaria. Kurtis et al. demon-
strated the protein PfSEP-1, which is involved in schizont egress, 
protected from lethal parasite challenge in a mouse model.6 On a 
related note, Dr Steven Williams, Gates Professor of Biology and 
Biochemistry at Smith College, gave an overview of neglected 
tropical diseases and advocated for breaking the cycle of disease 
and poverty to improve the economies of developing world coun-
tries. Williams, who has long worked in the areas of elephan-
tiasis and African river blindness, noted that despite 40 years of 
research, there are still no parasite vaccines available.
While not a neglected tropical disease, hepatitis C virus 
(HCV) is a considerable contributor to the global burden of dis-
ease, affecting an estimated 180 million people worldwide and 
causing a large proportion of chronic liver disease. Dr Phyllis 
Losikoff (Department of Medicine, Rhode Island Hospital and 
the Warren Alpert Medical School of Brown University) pre-
sented the problem of chronically HCV-infected individuals 
who are unable to maintain the broad CD4+ and CD8+ T cell 
responses required to resolve primary HCV infection. Losikoff 
et al. provide evidence in the current issue of HV&I7 demon-
strating the role of T regulatory (Treg) cells in the pathogen-
esis of chronic hepatitis C, as increased Treg populations in 
the tissues of HCV-infected patients correlated with persistent 
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year, the organizers award a conference scholarship to a student 
studying immunology or bioinformatics. This year’s recipient 
was Alicia Francis, a student of Jamaican heritage studying bio-
informatics at Washington Adventist University in Maryland. 
Francis aspires to become a pediatrician and plans to apply her 
bioinformatics training to the improvement of women’s and chil-
dren’s health. Furthermore, the annual “Polly Matzinger Fearless 
Scientist Award” recognizes women who entered scientific careers 
later in life or who returned to scientific careers after taking time 
off. This award, named for NIH scientist and thought leader in 
the field of immunology Dr Polly Matzinger, was presented to 
Dr Carey Medin, Assistant Research Professor at iCubed. Medin 
took time off from her research pursuits to raise her young fam-
ily but has since returned to academia; in her current position at 
iCubed in the laboratory of Dr Alan Rothman, she is analyzing 
the pathogenesis of dengue virus.
In conclusion, the Vaccine Renaissance Conference continues 
to provide an important forum for discussions of cutting-edge 
vaccine research to address unmet public health and biodefense 
needs. The small size of the conference creates ample opportunity 
for dialog, and a number of important scientific collaborations 
have resulted from encounters between researchers at this annual 
event.
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that could be expanded through the inclusion of small molecule 
attachments (e.g., nicotine vaccine) or full-length protein attach-
ments (e.g., norovirus vaccine).
Vaccine platform design was further explored in the last ses-
sion, “Vaccine Vectors and Human Microbiome.” In his pre-
sentation, Dr James Galen (Center for Vaccine Development at 
the University of Maryland School of Medicine) laid out a new 
strategy for the development of bacterial live vector vaccines. By 
integrating antigen-encoding gene cassettes into multiple chro-
mosomal sites within an attenuated Salmonella enteric serovar 
Typhi vaccine candidate, immunogenic chromosomally encoded 
antigens can be delivered without sacrificing loss of gene dosage 
or further attenuating the vaccine strain. Galen et al. demon-
strated the effect of integration site on expression levels of the 
green fluorescent protein (GFPuv), and notably observed that 
GFPuv expression increased in a growth phase-dependent man-
ner. As Galen points out in the current issue of HV&I,14 this 
novel platform expression technology holds high potential for 
facilitating development of multivalent live vector vaccines.
The final day of the conference was devoted to hands-on 
immunoinformatics and immunology training. This yearly event 
trains researchers to use the suite of immunoinformatics tools 
developed at EpiVax, Inc. and iCubed. Computational and lab-
based training provides opportunities for researchers to learn 
directly from the informatics and immunology experts in order 
to enhance their own research programs. This training session 
also provides an opportunity for researchers to network and 
establish collaborations.
A valuable role of the Vaccine Renaissance Conference is to 
support women and students from diverse and underrepresented 
backgrounds who are embarking on scientific careers. Each 
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